ATORX — Alligator Bioscience AB Balance Sheet
0.000.00%
- SEK122.19m
- SEK127.84m
- SEK57.77m
Annual balance sheet for Alligator Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 103 | 278 | 97.3 | 66.1 | 64.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.92 | 14.5 | 17.6 | 4.52 | 4.36 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 110 | 300 | 123 | 78.2 | 71.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 23.2 | 15.4 | 26.9 | 20.3 | 3.02 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 152 | 333 | 170 | 118 | 104 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 30.7 | 47.4 | 64.5 | 99.1 | 201 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 36.7 | 50.9 | 80.5 | 107 | 235 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 115 | 282 | 89.1 | 11.9 | -131 |
| Total Liabilities & Shareholders' Equity | 152 | 333 | 170 | 118 | 104 |
| Total Common Shares Outstanding |